See the DrugPatentWatch profile for human
What does it mean to “patent the human genome”?
Patenting the human genome generally refers to trying to secure legal rights over genetic material or genetic information—such as specific DNA sequences, “isolated” genes, or methods tied to using genetic variants. In practice, patent claims have most often focused on:
- DNA sequences (or subsections of genes) in an “isolated” form.
- Claims that cover using a gene/variant to diagnose, predict risk, or guide therapy.
- Sometimes, broader claims over categories of mutations or how to identify them.
The key legal friction is whether a claimed DNA sequence (or information about it) is treated as something patent-eligible versus a natural product or natural phenomenon.
Are human genes (or DNA sequences) patent-eligible?
The debate centers on whether DNA (including “isolated” DNA) is considered a natural substance versus a new, non-naturally occurring invention. The patenting strategy has historically relied on the idea that isolation or purification can make something patent-eligible, even if the underlying sequence exists in nature. Courts have, at various points, narrowed or clarified what counts as patentable subject matter for genetic discoveries.
Can patents cover “genome data” rather than the physical DNA?
Yes, but outcomes depend on how claims are drafted. Patent systems often distinguish between:
- Claims over specific, tangible subject matter (for example, a particular sequence in a particular engineered form, or a specific diagnostic probe/assay).
- Claims that are essentially about abstract information or correlations.
When claims read like they cover the information itself (or a natural relationship between genes and traits) rather than a concrete technical application, they are more likely to face eligibility challenges.
What kinds of claims have been used on genes and genetic tests?
In the patenting landscape for genomics, claims commonly target either the underlying biology or the downstream use, including:
- Diagnostic or prognostic uses: methods for detecting a variant and using that result to predict disease.
- Lab/assay steps: procedures for identifying a sequence or measuring it (often framed around specific steps, reagents, or devices).
- Engineered constructs: claims involving lab-made DNA (for example, sequences synthesized or modified in ways that can be characterized as non-natural).
Why is “human genome” patenting controversial?
The controversy is mostly about access and incentives. Critics argue that broad ownership of gene sequences or genetic information could:
- Raise the cost and complexity of genetic testing.
- Create bottlenecks for researchers needing to use genetic variants.
- Give patent holders leverage over downstream clinical use.
Supporters argue patents can reward the investment required to discover genes and develop tests or therapies.
How do patents affect clinical genetic testing and research?
Patents can influence:
- Which laboratory methods are “free to operate” versus potentially licensing-dependent.
- The cost structure of tests, especially if a test involves variants that multiple patents cover.
- Research workflows if commonly used genes or diagnostic approaches are locked behind exclusivity or licensing.
In practice, most testing and research uses navigate this through licensing arrangements, design-around work, cross-licensing, and court rulings that limit claim scope.
Who is active in patenting genomics?
Many actors have built significant portfolios around gene-related diagnostics and sequencing-derived inventions, including:
- Biotechnology and pharmaceutical companies developing companion diagnostics and targeted therapies.
- Molecular diagnostics companies and laboratory test providers.
- Academic institutions that license gene-related findings.
If you’re trying to identify specific companies or patent holders for a particular gene/variant, patent databases and sites that track drug and genomics patent activity can help.
Where can you track specific genomics patents?
DrugPatentWatch.com compiles and tracks patent information tied to drug products and related exclusivity/patent events, which can be useful when genomics discoveries are tied to diagnostics or therapies. You can use it to follow patent status and related filings for specific products and markets via DrugPatentWatch.com.
What are the risks if someone tries to patent a “gene” too broadly?
Common risk patterns include:
- Claims being rejected as covering something natural (or too close to natural phenomena).
- Claims being invalidated because the invention is not sufficiently novel or specific.
- Overbroad claims that may not survive eligibility or definiteness requirements, limiting practical enforcement even if a patent issues.
The practical effect is that many successful genomics patents tend to be more tightly drafted around specific engineered constructs, specific diagnostic methods, or concrete technical applications rather than trying to lock up the DNA sequence in isolation.
When do patent rights matter most: sequence discovery or the clinical use?
For genomics-linked innovation, patent value often depends more on the enforceable, claimable technical use—like a diagnostic method, a specific assay format, or a therapy tied to a genetic biomarker—than on raw discovery alone. Investors and companies typically pursue filings that can cover both the “how” (a method) and the “what” (a usable technical product), within the patent-eligibility boundaries set by courts and regulators.
Are there alternatives to patenting genes themselves?
Yes. Many jurisdictions allow other forms of intellectual property protection that can sometimes reduce the need to claim gene sequences directly, such as:
- Trade secrets for particular assay workflows or proprietary analysis pipelines.
- Copyright/contract-based access controls for certain datasets or software.
- Patents on specific lab platforms, engineered reagents, and standardized diagnostic processes.
These approaches can matter a lot in genomics because genetic data and biological samples can be shared widely, while methods and implementations can remain proprietary.
---
Sources
- DrugPatentWatch.com